DadFinStart your free week
DadFin › Stocks › Healthcare › ALKS

Alkermes plc (ALKS) stock score

Healthcare · Drug Manufacturers - Specialty & Generic · Ireland

$40.61 ▲ +1.25% today

13.6
Dad Score, out of 100
poor

Alkermes plc (ALKS) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, listed in Ireland. On DadFin's weekly run it scores 13.6 out of 100 on the Dad Score, a poor reading that places the business ahead of 14% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #835 of 974. Its strongest axes are quality, conviction and liquidity; its weakest are valuation and growth.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Below average
Quality
Strong
Growth
Weak
Price action
Weak
Risk
Below average
Conviction
Above average
Liquidity
Strong
Macro
Average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)109.9×
P/E (forward)23.1×
Dividend yield0.00%
Return on capital15.6%
Operating margin15.5%
Revenue growth (YoY)-5.2%
FCF yield7.3%
Net debt / EBITDA3.21×
Piotroski F-Score6 / 9
52-week change+34.7%
Market cap$7.0B
Next earningsOct 28, 2026

What subscribers see on ALKS

Start your free weekSubscriber? Open the full research →

Drug Manufacturers - Specialty & Generic peers

StockCompanyDad ScoreBandMarket cap
TAKTakeda Pharmaceutical Company Limi32.9weak$57.1B
TEVATeva Pharmaceutical Industries Lim93.6strong$46.1B
HLNHaleon plc64.5middling$38.7B
ZTSZoetis Inc.61.2middling$28.8B
UTHRUnited Therapeutics Corporation99.8strong$23.2B
VTRSViatris Inc.54.4middling$20.2B
NBIXNeurocrine Biosciences, Inc.98.4strong$14.6B
ELANElanco Animal Health Incorporated84.0good$11.1B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.